Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373445 | 0.95 | SMPD1 (0.71) | SMPD1PDE4BKMT2AMAOBCNR2 | |
| SCHEMBL28957152 | 0.94 | SMPD1 (0.73) | SMPD1PDE4BKMT2AMAOBCNR2 | |
| SCHEMBL10260429 | 0.94 | KMT2A (0.66) | SMPD1KMT2AMAOBFAAHMEN1 | |
| SCHEMBL7175524 | 0.92 | PDE4B (0.59) | SMPD1PDE4BKMT2APDE4DMAOB | |
| SCHEMBL10497745 | 0.92 | KMT2A (0.55) | SMPD1PDE4BKMT2AMAOBMEN1 | |
| SCHEMBL22502336 | 0.89 | THRA (0.64) | SMPD1PDE4BKMT2AMAOBMEN1 | |
| SCHEMBL13461243 | 0.88 | KMT2A (0.56) | SMPD1PDE4BKMT2APDE4APDE4C | |
| SCHEMBL15521570 | 0.88 | MAPK1 (0.68) | SMPD1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL17329448 | 0.88 | KMT2A (0.58) | SMPD1KMT2AMAOBMEN1 | |
| SCHEMBL3884522 | 0.88 | SMPD1 (0.68) | SMPD1PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5124455-A | Enzyme inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-23 | — | — | US | claimed |
| EP-0470805-A1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-02-12 | — | — | EP | claimed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015142928-A1 | DOSING OF CABOZANTINIB FORMULATIONS | EXELIXIS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2014145715-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-0928789-B1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6251897-B1 | TREATING DERMATITIS, ASTHMA | NIKKEN CHEMICALS CO., LTD (JP) | 2001-06-26 | — | — | US | disclosed |
| US-5998453-A | ANTIINFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-12-07 | — | — | US | disclosed |
| EP-0928789-A1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-07-14 | — | — | EP | disclosed |
| US-5869483-A | KIDNEY DISEASES | AMERICAN CYANAMID COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| CN-1029613-C | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflamatory agents | AMERICAN HOME PROD (US) | 1995-08-30 | — | — | CN | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0470805-B1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PROD (US) | 1994-09-07 | — | — | EP | disclosed |
| US-5124455-A | Enzyme inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-23 | — | — | US | disclosed |
| CN-1058771-A | Method for making of oxime carbamate and oxime carbonate ester and uses thereof | AMERICAN HOME PROD (US) | 1992-02-19 | — | — | CN | disclosed |
| EP-0470805-A1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-02-12 | — | — | EP | disclosed |
| EP-0198919-B1 | PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0198919-A1 | PHARMACEUTICAL PREPARATIONS. | SCHERING AG (DE) | 1986-10-29 | — | — | EP | disclosed |
| WO-1986002268-A1 | PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1986-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | SMPD1 3895/4885PDE4B 1254/4885KMT2A 117/4885 |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | IDH1, NTRK3, FGFR4 | SMPD1 1904/4885PDE4B 787/4885KMT2A 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.